Aclaris Therapeutics, Inc.
ACRS
$6.09
$0.071.08%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.63M | 2.00M | 1.30M | 3.30M | 1.78M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.63M | 2.00M | 1.30M | 3.30M | 1.78M |
| Cost of Revenue | 19.52M | 17.45M | 18.05M | 15.48M | 13.30M |
| Gross Profit | -17.89M | -15.45M | -16.76M | -12.18M | -11.52M |
| SG&A Expenses | 6.05M | 6.74M | 5.58M | 4.87M | 5.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.57M | 24.19M | 23.63M | 20.35M | 18.69M |
| Operating Income | -23.94M | -22.19M | -22.33M | -17.05M | -16.91M |
| Income Before Tax | -21.51M | -19.82M | -19.80M | -14.61M | -15.43M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.51M | -19.82M | -19.80M | -14.61M | -15.43M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.51M | -19.82M | -19.80M | -14.61M | -15.43M |
| EBIT | -23.94M | -22.19M | -22.33M | -17.05M | -16.91M |
| EBITDA | -23.94M | -22.19M | -22.32M | -17.04M | -16.88M |
| EPS Basic | -0.15 | -0.15 | -0.16 | -0.12 | -0.13 |
| Normalized Basic EPS | -0.09 | -0.10 | -0.10 | -0.07 | -0.07 |
| EPS Diluted | -0.15 | -0.15 | -0.16 | -0.12 | -0.13 |
| Normalized Diluted EPS | -0.09 | -0.10 | -0.10 | -0.07 | -0.07 |
| Average Basic Shares Outstanding | 142.74M | 128.81M | 122.66M | 122.62M | 122.58M |
| Average Diluted Shares Outstanding | 142.74M | 128.81M | 122.66M | 122.62M | 122.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |